Medifast (MED) Stock Analysis & AI Equity Report

Personal Products & Services USD Explore free reports

Medifast (MED) overview

Medifast (MED) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 386m and operating profit of USD -14.2m; the year-end share price was 10.68 USD and market capitalisation was USD 117m. Medifast is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Medifast's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 199mFY 2025
Share price10.68 USDFY 2025 year end
RevenueUSD 386mFY 2025
Operating profitUSD -14.2mFY 2025
Net earningsUSD -18.7mFY 2025
Market capitalisationUSD 117mFY 2025 year end

About Medifast

Medifast is a health and wellness company offering a coach-guided system focused on weight loss and metabolic health. Its program combines individualized support from independent coaches, community, a habit-creation framework, and nutrition plans and products. The company serves individuals seeking support with weight management, healthy habits, and broader well-being through a personalized, behavior-based approach.

Generate the Medifast report

Medifast is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Medifast and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Medifast

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.